MacroGenics, Inc. (MGNX) vs Protalix BioTherapeutics, Inc. (PLX)
- MacroGenics, Inc. MGNX 3.25 −3.56%
- Protalix BioTherapeutics, Inc. PLX 2.62 −2.96%
MacroGenics, Inc. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. MacroGenics, Inc. and Protalix BioTherapeutics, Inc. are of similar size ($217.5M and $214.7M). MacroGenics, Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 11.4×. Protalix BioTherapeutics, Inc. grew revenue faster over the last twelve months: 30.1% against 21.9%. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs −7.97%) and the higher return on invested capital (48.5% vs 0.00%). Across the 17 metrics below, Protalix BioTherapeutics, Inc. leads on 10 and MacroGenics, Inc. on 7.
Valuation
Profitability
| Metric | MGNX | PLX | Biotechnology median |
|---|---|---|---|
| Gross margin | 78.07% | 69.20% | 65.16% |
| Operating margin | (18.73%) | 28.89% | 0.00% |
| Net margin | (7.97%) | 23.50% | 0.00% |
| Free cash flow margin | (35.80%) | 9.51% | 0.00% |
| Return on equity | (32.61%) | 31.23% | (56.36%) |
| Return on assets | (4.94%) | 20.07% | (48.04%) |
| Return on invested capital | 0.00% | 48.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack